Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance.

Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, Deane RJ, Zhong E, Parisi M, Ciszewski J, Kasper RT, Deane R.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14771-6. doi: 10.1073/pnas.1302212110. Epub 2013 Aug 19.

2.

LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β.

Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G.

J Neurosci. 2012 Nov 14;32(46):16458-65. doi: 10.1523/JNEUROSCI.3987-12.2012.

3.

Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A.

Neuropharmacology. 2014 Apr;79:668-78. doi: 10.1016/j.neuropharm.2014.01.023. Epub 2014 Jan 24.

4.

Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance.

Shinohara M, Sato N, Kurinami H, Takeuchi D, Takeda S, Shimamura M, Yamashita T, Uchiyama Y, Rakugi H, Morishita R.

J Biol Chem. 2010 Jul 16;285(29):22091-102. doi: 10.1074/jbc.M110.102277. Epub 2010 May 14.

5.

Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Qosa H, Abuznait AH, Hill RA, Kaddoumi A.

J Alzheimers Dis. 2012;31(1):151-65. doi: 10.3233/JAD-2012-120319.

6.

Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.

Bayer TA, Schäfer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schüssel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14187-92. Epub 2003 Nov 14.

7.

Neuronal clearance of amyloid-β by endocytic receptor LRP1.

Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G.

J Neurosci. 2013 Dec 4;33(49):19276-83. doi: 10.1523/JNEUROSCI.3487-13.2013.

8.

Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier.

Storck SE, Meister S, Nahrath J, Meißner JN, Schubert N, Di Spiezio A, Baches S, Vandenbroucke RE, Bouter Y, Prikulis I, Korth C, Weggen S, Heimann A, Schwaninger M, Bayer TA, Pietrzik CU.

J Clin Invest. 2016 Jan;126(1):123-36. doi: 10.1172/JCI81108. Epub 2015 Nov 30.

9.

The role of choroid plexus in IVIG-induced beta-amyloid clearance.

Gu H, Zhong Z, Jiang W, Du E, Dodel R, Liu J, Farlow MR, Zheng W, Du Y.

Neuroscience. 2014 Jun 13;270:168-76. doi: 10.1016/j.neuroscience.2014.04.011. Epub 2014 Apr 16.

10.

Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier.

Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D.

Mol Cell Neurosci. 2013 Sep;56:255-62. doi: 10.1016/j.mcn.2013.06.004. Epub 2013 Jul 3.

PMID:
23831388
11.

Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.

Mare S, Penugonda S, Robinson SM, Dohgu S, Banks WA, Ercal N.

Peptides. 2007 Jul;28(7):1424-32. Epub 2007 May 18.

PMID:
17580097
12.

Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice.

Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, Zheng W, Du Y.

Neurosci Lett. 2011 Feb 18;490(1):16-20. doi: 10.1016/j.neulet.2010.12.017. Epub 2010 Dec 16.

13.

LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.

Pflanzner T, Janko MC, André-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, Pietrzik CU.

Neurobiol Aging. 2011 Dec;32(12):2323.e1-11. doi: 10.1016/j.neurobiolaging.2010.05.025. Epub 2010 Jul 13.

PMID:
20630619
14.

Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.

Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G.

J Neurosci. 2011 Feb 2;31(5):1644-51. doi: 10.1523/JNEUROSCI.5491-10.2011.

15.

Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice.

Maynard CJ, Cappai R, Volitakis I, Laughton KM, Masters CL, Bush AI, Li QX.

Cell Mol Neurobiol. 2009 Jul;29(5):757-67. doi: 10.1007/s10571-009-9401-7. Epub 2009 Apr 21.

PMID:
19381799
16.

Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease.

Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, Jishage K, Yamada H, Sasaguri H, Yokota S, Piao W, Tomimitsu H, Saido TC, Yanagisawa K, Terasaki T, Mizusawa H, Yokota T.

J Biol Chem. 2009 Nov 27;284(48):33400-8. doi: 10.1074/jbc.M109.054056. Epub 2009 Aug 13.

17.

Metals and amyloid-beta in Alzheimer's disease.

Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX.

Int J Exp Pathol. 2005 Jun;86(3):147-59. Review.

18.

Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.

Bachmeier C, Shackleton B, Ojo J, Paris D, Mullan M, Crawford F.

Neuromolecular Med. 2014 Dec;16(4):686-96.

19.

Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ.

Mol Med. 2011 Mar-Apr;17(3-4):149-62. doi: 10.2119/molmed.2010.00180. Epub 2010 Dec 17.

20.

Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ.

J Neuroinflammation. 2010 Mar 8;7:17. doi: 10.1186/1742-2094-7-17.

Items per page

Supplemental Content

Write to the Help Desk